Clinical Efficacy of Apremilast Combined with Hydroxychloroquine in the Treatment of Primary Sj?gren's Syndrome
Objective This study aimed to evaluate the clinical efficacy of Apremilast combined with Hydroxychloroquine in treating Primary Sjögren's Syndrome(PSS).Methods A retrospective study was conducted on 80 patients with primary Sjögren's Syndrome(PSS)treated at the Tongling City Hospital in Anhui Province from January 2019 to January 2023.Patients were di-vided into a combination therapy group(43 cases)who received treatment with Alramod combined with Hydroxychloroquine Sulfate tablets,and a control group(37 cases)who received Alramod alone.Clinical efficacy,salivary flow rate,tear secretion,Patient Reported Index in Sjögren's Syndrome(EULAR Sjögren's Syndrome Patient Reported Index,ESSPRI),Sjögren's Syn-drome Disease Activity Index(EULAR Sjögren's Syndrome Disease Activity Index,ESSDAI),as well as levels of Erythrocyte Sedimentation Rate(ESR),C-reactive Protein(CRP),and Immunoglobulin G(IgG)were observed in both groups.Additionally,the incidence of adverse reactions in both groups was monitored.Results After treatment,the total effective rate of the combina-tion group was higher than that of the control group;the saliva flow rate,tear secretion,ESSPRI,and ESSDAI scores of the com-bination group were better than those of the control group;the levels of ESR,CRP,and IgG in patients of the combination group were lower than those in the control group;there was no statistically significant difference in the incidence of adverse reactions between the two groups.Conclusion The combination of Elamod and Hydroxychloroquine Sulfate Tablets in the treatment of patients with primary Sjogren's Syndrome can significantly improve saliva and tear secretion,reduce inflammatory indicators,and has good safety,providing an effective combination therapy for the treatment of PSS.
NETL
NSTL
万方数据
